name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
A1087S	g.G3259T	p.A1087S			24821	S	S	MISSENSE	1357	1357	0						1323	T=34	34	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
A12G	g.C35G	p.A12G			28308	N	N	MISSENSE	1354	1357	0						2	G=1351	1351	G	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
A163V	g.C488T	p.A163V			22050	S	S	MISSENSE	1357	1357	0						1347	T=10	10	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
A243S	g.G727T	p.A243S			22289	S	S	MISSENSE	1356	1357	0						1265	T=91	91	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
A4068A	g.C12204T	p.A4068A			12469	ORF1ab	ORF1a	SILENT	1355	1357	0			nsp8	produced by both pp1a and pp1ab		1248	T=107	107	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
A903V	g.C2708T	p.A903V			2973	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1314	T=43	43	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
C336C	g.C1008T	p.C336C			22570	S	S	SILENT	1357	1357	0						1213	T=144	144	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D147D	g.C441T	p.D147D			706	ORF1ab	ORF1a	SILENT	1357	1357	0			leader protein	nsp1, produced by both pp1a and pp1ab		1340	T=17	17	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D215Y	g.G643T	p.D215Y			22205	S	S	MISSENSE	1357	1357	0						1349	T=8	8	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D348H	g.G1042C	p.D348H			29315	N	N	MISSENSE	596	1357	0						592	C=4	4	C	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D4344D	g.C13032T	p.D4344D			13297	ORF1ab	ORF1a	SILENT	1351	1357	0			nsp10	nsp10_CysHis, formerly known as growth-factor-like protein (GFL), produced by both pp1a and pp1ab		1343	T=8	8	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D4683D	g.T14049C	p.D4683D			14313	ORF1ab	ORF1b	SILENT	1357	1357	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		1349	C=8	8	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D5725D	g.C17175T	p.D5725D			17439	ORF1ab	ORF1b	SILENT	1357	1357	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		1310	T=47	47	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralâ€“nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9â€“11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationâ€”mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L5F'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D614G	g.A1841G	p.D614G			23403	S	S	MISSENSE	1357	1357	0						0	G=1357	1357	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
D61D	g.T183C	p.D61D			27384	ORF6	ORF6	SILENT	1356	1357	0						1339	C=17	17	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D6374D	g.C19122T	p.D6374D			19386	ORF1ab	ORF1b	SILENT	1279	1357	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		1262	T=17	17	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
D839Y	g.G2515T	p.D839Y			24077	S	S	MISSENSE	1356	1357	0						1003	T=353	353	T	G	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant near the internal fusion peptide shown in vitro to reduce Spike subunit fusion required for cell entry.	False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
E102K	g.G304A	p.E102K			25696	ORF3a	ORF3a	MISSENSE	1357	1357	0						1345	A=12	12	A	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
E1086E	g.A3258G	p.E1086E			3523	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1343	G=14	14	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
E472D	g.G1416T	p.E472D			1681	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp2	produced by both pp1a and pp1ab		1345	T=12	12	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Li et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Andreano et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.12.28.424451		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	monoclonal antibody serial passage escape	Baum et al. (2020)	http://dx.doi.org/10.1126/science.abd0831		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	transmissibility	Albertsen et al. (2021)	https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525	'Q52R', 'Q677H', 'F888L'	The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccine neutralization efficacy	Jangra et al. (2021)	https://doi.org/10.1016/S2666-5247(21		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccine neutralization efficacy	Solfrosi et al. (2021)	https://doi.org/10.1084/jem.20202756		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35â€“7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E484K	g.G1450A	p.E484K			23012	S	S	MISSENSE	1354	1357	0						0	A=1354	1354	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
E995K	g.G2983A	p.E995K			3248	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1286	A=71	71	A	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
F1062F	g.C3186T	p.F1062F			24748	S	S	SILENT	1356	1357	0						0	T=1356	1356	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
F2del	g.4_6delTTT	p.F2del			27204	ORF6	ORF6		1356	1357	0						0	GCA=1353	1353	GCA	GTTTCA						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
F3100F	g.C9300T	p.F3100F			9565	ORF1ab	ORF1a	SILENT	1343	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		0	T=1343	1343	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
F3153F	g.C9459T	p.F3153F			9724	ORF1ab	ORF1a	SILENT	1356	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		1344	T=12	12	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
F346F	g.C1038T	p.F346F			29311	N	N	SILENT	599	1357	0						596	T=3	3	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
F411F	g.C1233T	p.F411F			1498	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp2	produced by both pp1a and pp1ab		0	T=1357	1357	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
F6251F	g.C18753T	p.F6251F			19017	ORF1ab	ORF1b	SILENT	1356	1357	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		1280	T=76	76	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
F6L	g.C18A	p.F6L			27411	ORF7a	ORF7a	MISSENSE	1357	1357	0						1250	A=107	107	A	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
F888L	g.T2662C	p.F888L			24224	S	S	MISSENSE	1357	1357	0						0	C=1357	1357	C	T	transmissibility	Albertsen et al. (2021)	https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525	'Q52R', 'E484K', 'Q677H'	The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
F924F	g.C2772T	p.F924F			3037	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=1357	1357	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
G127C	g.G379T	p.G127C			644	ORF1ab	ORF1a	MISSENSE	1357	1357	0			leader protein	nsp1, produced by both pp1a and pp1ab		1349	T=8	8	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
G202G	g.C606T	p.G202G			27128	M	M	SILENT	1334	1357	0						1313	T=21	21	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
G2461G	g.T7383C	p.G2461G			7648	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1258	C=99	99	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
G334C	g.G1000T	p.G334C			1265	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp2	produced by both pp1a and pp1ab		1315	T=42	42	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
G3846G	g.T11538C	p.G3846G			11803	ORF1ab	ORF1a	SILENT	1356	1357	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		1243	C=113	113	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
G38G	g.A114G	p.G38G			27507	ORF7a	ORF7a	SILENT	1357	1357	0						1349	G=8	8	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
G38V	g.G113T	p.G38V			27506	ORF7a	ORF7a	MISSENSE	1357	1357	0						1342	T=15	15	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
G514G	g.A1542G	p.G514G			1807	ORF1ab	ORF1a	SILENT	982	1357	0			nsp2	produced by both pp1a and pp1ab		0	G=982	982	G	A						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
G5969G	g.C17907T	p.G5969G			18171	ORF1ab	ORF1b	SILENT	1355	1357	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		0	T=1355	1355	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
H3233Y	g.C9697T	p.H3233Y			9962	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		1348	T=9	9	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
H47N	g.C139A	p.H47N			27532	ORF7a	ORF7a	MISSENSE	1328	1357	0						1314	A=12	12	A	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
H78Y	g.C232T	p.H78Y			25624	ORF3a	ORF3a	MISSENSE	1357	1357	0						1346	T=11	11	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
I114T	g.T341C	p.I114T			606	ORF1ab	ORF1a	MISSENSE	1357	1357	0			leader protein	nsp1, produced by both pp1a and pp1ab		1205	C=152	152	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
I1276I	g.C3828T	p.I1276I			4093	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1265	T=92	92	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
I131M	g.A393G	p.I131M			28666	N	N	MISSENSE	1345	1357	0						1335	G=10	10	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
I3145V	g.A9433G	p.I3145V			9698	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		1341	G=16	16	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
I5804I	g.C17412T	p.I5804I			17676	ORF1ab	ORF1b	SILENT	1355	1357	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		1344	T=11	11	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
I82T	g.T245C	p.I82T			26767	M	M	MISSENSE	1357	1357	0						0	C=1357	1357	C	T	homoplasy	Shen et al. (2021)	https://doi.org/10.1080/22221751.2021.1922097		This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
K2589R	g.A7766G	p.K2589R			8031	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1320	G=37	37	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
K6958R	g.A20873G	p.K6958R			21137	ORF1ab	ORF1b	MISSENSE	1352	1357	0			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		453	G=899	899	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
K798K	g.G2394A	p.K798K			2659	ORF1ab	ORF1a	SILENT	1353	1357	0			nsp2	produced by both pp1a and pp1ab		0	A=1353	1353	A	G						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
L108F	g.C322T	p.L108F			25714	ORF3a	ORF3a	MISSENSE	1357	1357	0						1342	T=15	15	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L124L	g.C372T	p.L124L			26894	M	M	SILENT	1309	1357	0						1299	T=10	10	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L1627L	g.C4879T	p.L1627L			5144	ORF1ab	ORF1a	SILENT	1351	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1339	T=12	12	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L1643L	g.C4927T	p.L1643L			5192	ORF1ab	ORF1a	SILENT	1352	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1338	T=14	14	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L176P	g.T527C	p.L176P			22089	S	S	MISSENSE	1357	1357	0						1349	C=8	8	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L21F	g.C61T	p.L21F			26305	E	E	MISSENSE	1354	1357	0						0	T=1354	1354	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
L3320L	g.A9960G	p.L3320L			10225	ORF1ab	ORF1a	SILENT	1357	1357	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		1250	G=107	107	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L3505L	g.C10513T	p.L3505L			10778	ORF1ab	ORF1a	SILENT	1354	1357	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		1346	T=8	8	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L3606F	g.G10818T	p.L3606F			11083	ORF1ab	ORF1a	MISSENSE	1355	1357	0	mask	highly_homoplasic	nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		1342	T=13	13	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L3840L	g.C11520T	p.L3840L			11785	ORF1ab	ORF1a	SILENT	1356	1357	0			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab		1309	T=47	47	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L4045L	g.C12135T	p.L4045L			12400	ORF1ab	ORF1a	SILENT	1356	1357	0			nsp8	produced by both pp1a and pp1ab		1349	T=7	7	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L5040F	g.G15120T	p.L5040F			15384	ORF1ab	ORF1b	MISSENSE	1357	1357	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		1204	T=153	153	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	1292	1357	0	mask	highly_homoplasic				1237	T=55	55	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	1292	1357	0	mask	highly_homoplasic				1237	T=55	55	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L5F	g.C13T	p.L5F			21575	S	S	MISSENSE	1292	1357	0	mask	highly_homoplasic				1237	T=55	55	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
L6820L	g.A20460G	p.L6820L			20724	ORF1ab	ORF1b	SILENT	1355	1357	0			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only		0	G=1354	1354	G	A						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
L948L	g.T2844C	p.L948L			24406	S	S	SILENT	1356	1357	0						1341	C=15	15	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
M153I	g.G459T	p.M153I			22021	S	S	MISSENSE	1357	1357	0						1309	T=48	48	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
M3087I	g.G9261T	p.M3087I			9526	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		1349	T=8	8	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
M6240I	g.G18720T	p.M6240I			18984	ORF1ab	ORF1b	MISSENSE	1357	1357	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		1349	T=8	8	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
N1709N	g.C5127T	p.N1709N			5392	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1348	T=9	9	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
N2405S	g.A7214G	p.N2405S			7479	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1323	G=34	34	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
N2523N	g.C7569T	p.N2523N			7834	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1323	T=34	34	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
N4235N	g.C12705T	p.N4235N			12970	ORF1ab	ORF1a	SILENT	1349	1357	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		1332	T=17	17	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
N6335N	g.C19005T	p.N6335N			19269	ORF1ab	ORF1b	SILENT	1354	1357	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		1337	T=17	17	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
P104L	g.C311T	p.P104L			25703	ORF3a	ORF3a	MISSENSE	1357	1357	0						1348	T=9	9	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
P1263L	g.C3788T	p.P1263L			25350	S	S	MISSENSE	1357	1357	0						1326	T=31	31	T	C	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant in the cytoplasmic tail, shown in vitro to increase Spike subunit fusion required for cell entry	False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
P142P	g.A426G	p.P142P			28699	N	N	SILENT	1344	1357	0						0	G=1342	1342	G	A						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
P1977S	g.C5929T	p.P1977S			6194	ORF1ab	ORF1a	MISSENSE	1350	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1323	T=27	27	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
P3504L	g.C10511T	p.P3504L			10776	ORF1ab	ORF1a	MISSENSE	1354	1357	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		1337	T=17	17	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
P36S	g.C106T	p.P36S			27999	ORF8	ORF8	MISSENSE	1357	1357	0						1345	T=12	12	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
P4715F	g.CC14143_14144TT	p.P4715F			14407	ORF1ab	ORF1b		1357	1357	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		0	TT=1357	1357	TT	CC						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
Q1071R	g.A3212G	p.Q1071R			24774	S	S	MISSENSE	1357	1357	0						1348	G=9	9	G	A						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
Q14H	g.G42T	p.Q14H			21604	S	S	MISSENSE	1274	1357	0						1244	T=30	30	T	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
Q52R	g.A155G	p.Q52R			21717	S	S	MISSENSE	1326	1357	0						0	G=1326	1326	G	A	transmissibility	Albertsen et al. (2021)	https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525	'E484K', 'Q677H', 'F888L'	The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
Q677H	g.G2031C	p.Q677H			23593	S	S	MISSENSE	1357	1357	0						0	C=1357	1357	C	G	transmissibility	Albertsen et al. (2021)	https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525	'Q52R', 'E484K', 'F888L'	The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
Q94X	g.C280T	p.Q94X			27673	ORF7a	ORF7a	NONSENSE	1324	1357	0						1301	T=23	23	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
R14C	g.C40T	p.R14C			28313	N	N	MISSENSE	1354	1357	0						1337	T=17	17	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
R24R	g.C72T	p.R24R			337	ORF1ab	ORF1a	SILENT	1357	1357	0			leader protein	nsp1, produced by both pp1a and pp1ab		1347	T=10	10	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
R2949R	g.C8847T	p.R2949R			9112	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		1346	T=11	11	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
R41Q	g.G122A	p.R41Q			28395	N	N	MISSENSE	1350	1357	0						1336	A=14	14	A	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
R41R	g.G123A	p.R41R			28396	N	N	SILENT	1350	1357	0						1235	A=115	115	A	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S1841F	g.C5522T	p.S1841F			5787	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1350	T=7	7	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S2273F	g.C6818T	p.S2273F			7083	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1346	T=11	11	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S2500S	g.C7500T	p.S2500S			7765	ORF1ab	ORF1a	SILENT	1354	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1342	T=12	12	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S2631S	g.T7893C	p.S2631S			8158	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1343	C=14	14	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S3044T	g.T9130A	p.S3044T			9395	ORF1ab	ORF1a	MISSENSE	1354	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		1347	A=7	7	A	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S36P	g.T106C	p.S36P			27499	ORF7a	ORF7a	MISSENSE	1357	1357	0						1350	C=7	7	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S40L	g.C119T	p.S40L			25511	ORF3a	ORF3a	MISSENSE	1357	1357	0						1347	T=10	10	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S74S	g.C222T	p.S74S			25614	ORF3a	ORF3a	SILENT	1357	1357	0						1347	T=10	10	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
S92L	g.C275T	p.S92L			25667	ORF3a	ORF3a	MISSENSE	1357	1357	0						1350	T=7	7	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T1303I	g.C3908T	p.T1303I			4173	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1350	T=7	7	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T1504I	g.C4511T	p.T1504I			4776	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1310	T=47	47	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T2007I	g.C6020T	p.T2007I			6285	ORF1ab	ORF1a	MISSENSE	1353	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		0	T=1353	1353	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
T205I	g.C614T	p.T205I			28887	N	N	MISSENSE	1329	1357	0						0	T=1329	1329	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
T265T	g.T795G	p.T265T			29068	N	N	SILENT	716	1357	0						670	G=46	46	G	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T28I	g.C83T	p.T28I			27476	ORF7a	ORF7a	MISSENSE	1357	1357	0						1244	T=113	113	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T3308T	g.C9924A	p.T3308T			10189	ORF1ab	ORF1a	SILENT	1357	1357	0			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab		1347	A=10	10	A	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T4031I	g.C12092T	p.T4031I			12357	ORF1ab	ORF1a	MISSENSE	1356	1357	0			nsp8	produced by both pp1a and pp1ab		1341	T=15	15	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T4129I	g.C12386T	p.T4129I			12651	ORF1ab	ORF1a	MISSENSE	1348	1357	0			nsp8	produced by both pp1a and pp1ab		1220	T=128	128	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T4159I	g.C12476T	p.T4159I			12741	ORF1ab	ORF1a	MISSENSE	1351	1357	0			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab		1304	T=47	47	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T5805T	g.G17415T	p.T5805T			17679	ORF1ab	ORF1b	SILENT	1357	1357	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		1340	T=17	17	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T5825I	g.C17474T	p.T5825I			17738	ORF1ab	ORF1b	MISSENSE	1356	1357	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		1210	T=146	146	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T6028T	g.C18084T	p.T6028T			18348	ORF1ab	ORF1b	SILENT	1356	1357	0			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only		1340	T=16	16	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
T89I	g.C266T	p.T89I			25658	ORF3a	ORF3a	MISSENSE	1357	1357	0						1204	T=153	153	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V114F	g.G340T	p.V114F			28233	ORF8	ORF8	MISSENSE	1357	1357	0						1191	T=166	166	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V2019F	g.G6055T	p.V2019F			6320	ORF1ab	ORF1a	MISSENSE	1355	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1344	T=11	11	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V2776V	g.T8328C	p.V2776V			8593	ORF1ab	ORF1a	SILENT	1356	1357	0			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab		0	C=1356	1356	C	T						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
V337F	g.G1009T	p.V337F			1274	ORF1ab	ORF1a	MISSENSE	1357	1357	0			nsp2	produced by both pp1a and pp1ab		1349	T=7	7	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V4073V	g.C12219T	p.V4073V			12484	ORF1ab	ORF1a	SILENT	1356	1357	0			nsp8	produced by both pp1a and pp1ab		1349	T=7	7	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V5366V	g.C16098T	p.V5366V			16362	ORF1ab	ORF1b	SILENT	1356	1357	0			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only		1346	T=10	10	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V620V	g.C1860T	p.V620V			23422	S	S	SILENT	1357	1357	0						1348	T=9	9	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V757V	g.C2271T	p.V757V			2536	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp2	produced by both pp1a and pp1ab		453	T=904	904	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V93F	g.G277T	p.V93F			27670	ORF7a	ORF7a	MISSENSE	1326	1357	0						1279	T=47	47	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
V951V	g.G2853T	p.V951V			24415	S	S	SILENT	1356	1357	0						1331	T=25	25	T	G						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
Y145del	g.432_434delTTA	p.Y145del			21990	S	S		1224	1357	0						8	TTTAC=1216	1216	TTTAC	TTTATTAC	convalescent plasma escape	Li et al. (2020)	https://www.sciencedirect.com/science/article/abs/pii/S0092867420308771		Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
Y145del	g.432_434delTTA	p.Y145del			21990	S	S		1224	1357	0						8	TTTAC=1216	1216	TTTAC	TTTATTAC	convalescent plasma escape	McCarthy et al. (2021)	https://doi.org/10.1126/science.abf6950		Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.	False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
Y1868Y	g.C5604T	p.Y1868Y			5869	ORF1ab	ORF1a	SILENT	1357	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1320	T=37	37	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
Y204Y	g.T612C	p.Y204Y			27134	M	M	SILENT	1334	1357	0						1327	C=7	7	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
Y2504H	g.T7510C	p.Y2504H			7775	ORF1ab	ORF1a	MISSENSE	1356	1357	0			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab		1322	C=34	34	C	T						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
Y4461Y	g.C13383T	p.Y4461Y			13647	ORF1ab	ORF1b	SILENT	1357	1357	0			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only		1348	T=9	9	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
g.A29776T	g.A29776T				29776	intergenic	intergenic		3	1357	0						0	T=3	3	T	A						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
g.C-160T	g.C-160T				106	ORF1ab	intergenic		1357	1357	0						1310	T=47	47	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
g.C-25T	g.C-25T				241	ORF1ab	intergenic		1357	1357	0						0	T=1357	1357	T	C						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
g.C-60T	g.C-60T				206	ORF1ab	intergenic		1357	1357	0						1347	T=10	10	T	C						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
g.CTTTAATC29679CTTAATC	g.CTTTAATC29679CTTAATC				29679	intergenic	intergenic		541	1357	0						537	CTTAATC=4	4	CTTAATC	CTTTAATC						False	B.1.525	B.1.525=False	de_escalated	17-Mar-2021		
g.G-15T	g.G-15T				29543	ORF10	intergenic		577	1357	0						3	T=574	574	T	G						False	B.1.525	B.1.525=True	de_escalated	17-Mar-2021		
